We aim to fast-track science, fund innovative research, and push progress forward to uncover the next generation therapies. With this integrated approach, our goal is to stop PF in its tracks.
What We Do
Three Lakes Consortium for PF (TLC4PF)
The Three Lakes Consortium for PF (TLC4PF) aims to accelerate therapies for the treatment of PF.
B4PF: Understanding Early Disease
To develop therapies that prevent the development of PF, it is essential to study the earliest aspects of disease pathogenesis.
A Global Collaboration for PF
Centre of Research Excellence in Pulmonary Fibrosis (CRE-PF) is a clinically focused research program funded by the Australian National Health and Medical Research Council.
The PRECISIONS Study
Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) is a comprehensive, multicenter, and multi-investigator study.
Breath Biopsy for Early PF Detection
Metabolic changes associated with IPF and interstitial lung abnormality (ILA) may lead to the production of unique, volatile, organic compounds (VOCs) detectable in breath.
The Impact of Antimicrobial Therapy in IPF
Clean-UP IPF was the first pragmatic trial in IPF that looks at whether antimicrobial therapy would improve hospitalization or decrease death.
Targeted Therapies for PF
Selectively targeting the cells that drive PF would protect the patients from systemic side effects associated with therapies.
EGCG for IPF
EGCG was discovered as an antifibrotic in pre-clinical in vivo studies and its mechanism of action blocking collagen accumulation published in 2017.